All Articles

NuScale Power’s revenue vanished in Q2, but its cash hoard swelled to $1.9B. It’s a high-stakes pivot from design fees to a costly industrial reality.

The TiO2 giant swung from loss to profit, beating estimates. A deep dive into how cost-cutting and market share gains are redefining success in a tough economy.

As Biofrontera preps its Q2 report, investors weigh record revenue and expanded margins against persistent losses and a critical need for cash flow breakeven.

The warehouse giant posts another stellar month with 10.7% sales growth, but its nearly 18% surge in digitally-enabled sales reveals a deeper strategy.

As Founder Rusty Hutson Jr. assumes the dual CEO-Chairman role at Diversified Energy, the move consolidates leadership but raises critical corporate governance questions.

Amid economic volatility, PhenixFIN posts stellar Q3 results, driven by a rising NAV per share, resilient credit quality, and savvy capital management.

Facing the biotech cash crunch, Context Therapeutics shelves one drug to double down on two others, a strategic pivot that secures its future into late 2027.

One Liberty Properties' stellar Q2 results aren't just good numbers; they're proof of a masterfully executed pivot to industrial real estate, a case study in navigating market shifts.

As York Space Systems names an interim CFO on the eve of its earnings report, the move signals a bid for stability in a volatile public market.

Traeger's revenue is down 17%, but its new Lowe's deal and aggressive cost-cutting signal a bold, risky pivot. Is this the right recipe for growth?

Beyond record revenues, Park-Ohio's Q2 results reveal a strategic pivot, leveraging AI, aerospace, and electrification to forge a less cyclical, high-growth future.

With soaring revenues and a landmark Microsoft AI deal, A10 Networks is redefining its role. Is this the playbook for winning the AI infrastructure wars?

Cytek Biosciences raises 2026 guidance on new tech, but rising costs and a wider net loss have investors questioning its path to sustainable profit.

With a new $345 genome and major clinical wins, PacBio pushes boundaries. But can its strategic restructuring and bold R&D overcome mounting financial losses?

Gloo's acquisition of Cedarstone isn't just a merger. It's a strategic pivot to sell results, not software, aiming to unburden nonprofits with AI-powered services.

The agentic customer platform posts 20% revenue growth and a return to profitability, yet a softer forecast reveals underlying market pressures.

KORU Medical posts record profits, but the real story is its strategic overhaul. We dissect its oncology pivot and digital tech bet for long-term value.

The hormone optimization leader's stock tumbles after Q2 results show a net loss and declining revenue, revealing the prolonged impact of its January recall.

The clean-living brand's revenue is down, but profits and confidence are soaring. A deep dive into how strategic cuts are building a more durable company.

A new $105M SPAC enters the fray. We examine its veteran leadership, its cross-sector strategy, and what it takes to win in today's SPAC market.